Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Rheumatology

Understanding Systemic Sclerosis: What It Is and What to Expect

At a Glance

Systemic sclerosis (scleroderma) is a rare autoimmune disease causing blood vessel damage and tissue scarring. While currently incurable, modern personalized treatments and early monitoring of the skin, heart, and lungs can effectively manage symptoms and slow disease progression.

Receiving a diagnosis of systemic sclerosis (SSc)—also known as scleroderma—can feel overwhelming. It is a rare, complex, and chronic condition, and it is completely normal to feel scared, anxious, or even grief-stricken [1][2]. You may be navigating a “diagnostic odyssey” where it took time to find answers, or you may be reeling from the suddenness of the news [3].

The most important thing to know right now is that you are not alone, and modern medicine has more tools to manage this condition than ever before [4]. While SSc is a serious diagnosis, it is also a highly heterogeneous disease, meaning it looks very different from one person to the next [5].

What is Systemic Sclerosis?

At its core, SSc is an autoimmune disease where the body’s defense system mistakenly attacks its own tissues [6]. Doctors view SSc as a “triad”—three interconnected processes that happen in the body:

  1. Autoimmunity (Immune Dysfunction): Your immune system becomes overactive and produces autoantibodies (proteins that attack your own cells). These antibodies send false “danger signals” to your body [7][8].
  2. Vasculopathy (Blood Vessel Damage): The small blood vessels become damaged and narrowed [9]. This is often the very first sign of the disease, frequently showing up as Raynaud’s phenomenon (fingers or toes turning white, blue, or red in response to cold or stress) [10][11].
  3. Fibrosis (Scarring): In response to the immune signals and vessel damage, your body overproduces collagen. Think of this like a wound-healing process that doesn’t know how to turn off. This leads to fibrosis, or the thickening and hardening of the skin and sometimes internal organs [12][13].

Three Stabilizing Facts

When facing a new diagnosis, it helps to ground yourself in what we know from current research:

  • Earlier Diagnosis is Now Possible: In 2013, the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) updated the classification criteria for SSc [14]. These modern standards allow doctors to identify the disease much earlier than in the past—often before significant organ damage occurs—giving you a head start on management [15][16].
  • Treatment is Becoming Personalized: We are moving away from a “one size fits all” approach. Doctors now use your specific antibody profile and clinical symptoms to tailor treatments [17]. Options range from traditional immune-modulating drugs to newer therapies like rituximab or even stem cell transplantation for severe cases [18][19].
  • Proactive Management Works: While there is currently no cure, there are effective ways to manage symptoms and protect your organs. Emerging research focuses on “disease-modifying” strategies that aim to stabilize or even reverse the fibrotic (scarring) process [20][21].

Your Path Forward

Because SSc is so variable, your journey will be unique [5]. You may have the limited form, which primarily affects the skin of the hands, face, and feet, or the diffuse form, which can progress more quickly and involve larger areas of skin or internal organs [14][22].

Your medical team will monitor you closely using “baseline” tests for your lungs, heart, and kidneys [4]. This proactive monitoring is designed to catch any changes early, when they are most treatable. Your role is to be an active partner in this care, tracking your symptoms and communicating openly with your rheumatologist.

Common questions in this guide

What are the first signs of systemic sclerosis?
One of the earliest signs is often Raynaud's phenomenon. This is a condition where the small blood vessels narrow, causing fingers or toes to turn white, blue, or red in response to cold temperatures or stress.
What is the difference between limited and diffuse systemic sclerosis?
Limited systemic sclerosis primarily affects the skin of the hands, face, and feet. The diffuse form can progress more quickly and involve larger areas of the skin as well as internal organs.
What causes the scarring in systemic sclerosis?
Doctors view the disease as a combination of three interconnected processes. These include immune system dysfunction, blood vessel damage, and fibrosis, which causes the body to overproduce collagen and scar tissue.
Why does my doctor want to test my lungs and heart?
Systemic sclerosis can cause scarring in internal organs over time. Establishing baseline tests for your heart, lungs, and kidneys allows your medical team to monitor for any changes and start protective treatments as early as possible.
What are the treatment options for systemic sclerosis?
Treatments are tailored to your specific symptoms and autoantibody profile. Options range from traditional immune-modulating drugs to newer targeted therapies like rituximab, JAK inhibitors, or even stem cell transplantation for severe cases.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific autoantibodies were found in my blood tests, and what do they tell us about my likely disease course?
  2. 2.Based on my initial assessment, which 'subset' of systemic sclerosis do I currently fall into?
  3. 3.What is my baseline lung function and heart health, and how often will we monitor these?
  4. 4.Are there specific clinical trials or newer treatments like rituximab or JAK inhibitors that might be appropriate for my situation?
  5. 5.How can we differentiate between active inflammation and permanent scarring (fibrosis) as my symptoms evolve?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    The Effect of Telerehabilitation-Based Self-Management Programme on Individuals With Scleroderma.

    Karakuş E, Sari F, Avanoğlu Güler A, et al.

    Musculoskeletal care 2024; (22(4)):e1947 doi:10.1002/msc.1947.

    PMID: 39327669
  2. 2

    Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study.

    Lee YC, Fox RS, Kwakkenbos L, et al.

    The Lancet. Rheumatology 2021; (3(12)):e844-e854 doi:10.1016/S2665-9913(21)00318-0.

    PMID: 38287631
  3. 3

    Systemic sclerosis - the dermatological perspective.

    Sticherling M

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019; (17(7)):716-728 doi:10.1111/ddg.13887.

    PMID: 31364293
  4. 4

    Frequency and determinants of use of immunosuppressants in the Australian Scleroderma Cohort Study.

    Fairley JL, Hansen D, Proudman S, et al.

    Journal of scleroderma and related disorders 2025; (10(3)):311-321 doi:10.1177/23971983251342690.

    PMID: 40416409
  5. 5

    Systemic sclerosis and scleroderma renal crisis in African American patients.

    Kotamarti R, Hackshaw KV

    Journal of the National Medical Association 2025; (117(3)):179-184 doi:10.1016/j.jnma.2025.04.006.

    PMID: 40368669
  6. 6

    Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.

    Graßhoff H, Fourlakis K, Comdühr S, Riemekasten G

    Biomedicines 2022; (10(9)) doi:10.3390/biomedicines10092150.

    PMID: 36140251
  7. 7

    Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis.

    Paul S, Kaplan MH, Khanna D, et al.

    Nature communications 2022; (13(1)):7074 doi:10.1038/s41467-022-34775-8.

    PMID: 36400785
  8. 8

    Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis.

    Binda M, Moccaldi B, Civieri G, et al.

    International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25042299.

    PMID: 38396976
  9. 9

    Prevalence and severity of complicated Raynaud's phenomenon in limited and diffuse systemic sclerosis: a multicenter study in Iraq.

    Jaafar F, Moayad Z, Gorial F, Alkazzaz A

    Reumatologia 2025; (63(6)):383-388 doi:10.5114/reum/207625.

    PMID: 41583572
  10. 10

    Assessing digital vasculopathy in systemic sclerosis.

    Herrick AL

    Rheumatology (Oxford, England) 2026; (65(2)) doi:10.1093/rheumatology/keag081.

    PMID: 41689194
  11. 11

    The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy.

    Abdulle AE, Diercks GFH, Feelisch M, et al.

    Frontiers in physiology 2018; (9()):1177 doi:10.3389/fphys.2018.01177.

    PMID: 30197602
  12. 12

    Are systemic sclerosis and localized scleroderma (morphea) part of a common disease spectrum? A systematic review on their coexistence.

    De Rosa C, Di Marco G, Bottino V, et al.

    Clinics in dermatology 2025; (43(6)):850-858 doi:10.1016/j.clindermatol.2025.09.032.

    PMID: 41043651
  13. 13

    Healthcare utilization and economic burden in systemic sclerosis: a systematic review.

    Martin Calderon L, Chaudhary M, Pope JE

    Rheumatology (Oxford, England) 2022; (61(8)):3123-3131 doi:10.1093/rheumatology/keab847.

    PMID: 34849627
  14. 14

    Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.

    Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, et al.

    The Journal of rheumatology 2015; (42(12)):2327-31 doi:10.3899/jrheum.150144.

    PMID: 26472418
  15. 15

    Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

    Araújo FC, Camargo CZ, Kayser C

    Rheumatology international 2017; (37(11)):1825-1833 doi:10.1007/s00296-017-3787-1.

    PMID: 28819792
  16. 16

    Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic.

    Melchor S, Joven BE, Andreu JL, et al.

    Seminars in arthritis and rheumatism 2016; (46(3)):350-355 doi:10.1016/j.semarthrit.2016.05.007.

    PMID: 27373498
  17. 17

    Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications.

    Massay R, Zahn C, Tsou PS

    Current opinion in rheumatology 2025; (37(6)):373-383 doi:10.1097/BOR.0000000000001126.

    PMID: 40916990
  18. 18

    Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.

    Ebata S, Yoshizaki A, Oba K, et al.

    The Lancet. Rheumatology 2021; (3(7)):e489-e497 doi:10.1016/S2665-9913(21)00107-7.

    PMID: 38279402
  19. 19

    Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.

    Henes J, Oliveira MC, Labopin M, et al.

    Haematologica 2021; (106(2)):375-383 doi:10.3324/haematol.2019.230128.

    PMID: 31949011
  20. 20

    Fibrosis mechanisms in systemic sclerosis and new potential therapies.

    Barile R, Rotondo C, Rella V, et al.

    Postgraduate medical journal 2025; (101(1198)):680-689 doi:10.1093/postmj/qgae169.

    PMID: 39656890
  21. 21

    Systemic sclerosis.

    Hughes M, Herrick AL

    British journal of hospital medicine (London, England : 2005) 2019; (80(9)):530-536 doi:10.12968/hmed.2019.80.9.530.

    PMID: 31498665
  22. 22

    The role of nailfold videocapillaroscopy in patients with systemic sclerosis.

    Kubo S, Smith V, Cutolo M, Tanaka Y

    Immunological medicine 2018; (41(3)):113-119 doi:10.1080/25785826.2018.1531189.

    PMID: 30938276

This page provides introductory information about systemic sclerosis for educational purposes only. Always consult your rheumatologist for a personalized diagnosis and medical care plan.

Get notified when new evidence is published on Systemic sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.